Poolbeg Pharma (LON:POLB) Shares Down 0.7% – What’s Next?

Poolbeg Pharma PLC (LON:POLB)’s stock price was down 0.7% during trading on Wednesday . The company traded as low as GBX 7.10 ($0.09) and last traded at GBX 7.10 ($0.09). Approximately 392,788 shares were traded during trading, a decline of 76% from the average daily volume of 1,611,117 shares. The stock had previously closed at GBX 7.15 ($0.09).

Poolbeg Pharma Price Performance

The company has a 50-day moving average price of GBX 7.68 and a 200 day moving average price of GBX 10.13. The firm has a market capitalization of £35.50 million, a PE ratio of -710.00 and a beta of 2.11.

About Poolbeg Pharma

Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class broad spectrum RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.